Message from Top Management

We would like to express our sincere appreciation for your continued support.

I am honored to have been appointed President as of April 1, 2026. Founded in 1929, Wakamoto Pharmaceutical has a history spanning nearly a century, and I feel a deep sense of responsibility in carrying this legacy forward.

Since the launch of “Wakamoto,” we have remained committed to contributing to people’s health as our core social mission. The strong business foundation and trust we enjoy today are the result of the invaluable support of our many stakeholders, to whom I extend my heartfelt gratitude.

Our corporate philosophy—“Contributing to healthy and vibrant lives by providing a broad range of health-related products that enhance quality of life (QOL)”—clearly defines the vision we strive to achieve. It reflects our unwavering commitment to contributing to a sustainable society through our daily business activities.

To realize this vision, we have identified key management priorities (materiality issues) and formulated our medium-term management plan, “Wakamoto 100 – Inheritance and Challenge.” Under this plan, we are integrating our business, financial, and sustainability strategies. We are committed to the steady execution of growth strategies that enhance capital efficiency, maximizing the value of our business expertise, human resources, the Wakamoto brand, and our sales assets, while creating new value for the next century.

In our pharmaceutical business, as a specialty pharma company in the field of ophthalmology, we develop and market pharmaceuticals, medical devices, and health foods. Through initiatives such as intraocular lenses and perioperative pharmaceuticals, we will enhance synergies across our portfolio and further strengthen the value we provide to the medical community.

In our healthcare business, we are increasing production capacity through investment in facilities for the “Strong Wakamoto” production line. At the same time, we are advancing product planning and development that address unmet customer needs, including lactobacillus-based toothpaste “Avantbise” and femcare products centered on the Wakamoto brand.

In our global business, we are strengthening our international foundation by expanding sales in Asian markets, developing Wakamoto brand products through cross-border e-commerce, and growing our lactobacillus-related business.

By continuing to inherit the values we have long cherished while boldly challenging ourselves in new areas without fear of change, all employees of Wakamoto Pharmaceutical will work together as one to remain a company trusted by society.

We sincerely appreciate your continued support and guidance.